← Back to Search

Cancer Preventive Agent

Nutritional Supplementation for Lung Cancer

Phase < 1
Waitlist Available
Led By Daniel Spakowicz, PhD, MS
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial is testing whether black raspberry nectar can change the gut microbiome and reduce inflammation that may lead to lung cancer.

Eligible Conditions
  • Lung Cancer
  • Tobacco-Related Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Biologic responses to the black raspberry (BRB) nectar
Changes in stool microbe relative abundances
Inflammatory markers found in nasal brushings
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm II (placebo, BRB nectar, biospecimen collection)Experimental Treatment4 Interventions
Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
Group II: Arm I (BRB nectar, placebo, biospecimen collection)Experimental Treatment4 Interventions
Patients receive BRB nectar PO BID for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 2
~1730
Nutritional Supplementation
2019
Completed Early Phase 1
~220
Placebo Administration
2018
Completed Phase 3
~2540

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
290,071 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,571 Total Patients Enrolled
Daniel Spakowicz, PhD, MSPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials
150 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical research protocol impose an age restriction on its participants?

"This medical trial has defined a range of eligibility in regards to age, with the minimum being 55 and the maximum 77."

Answered by AI

Is it possible to partake in this research project?

"The trial is open to 96 people with tobacco-related carcinoma between the ages of 55 and 77. The essential requirements include a 30 pack-year smoking history, status as either an ongoing smoker or one who has quit in the last 15 years, agreement to take a standardised vitamin/mineral supplement, and abstention from other nutritional supplements for its duration."

Answered by AI

Is enrollment for this clinical experiment currently open?

"According to clinicaltrials.gov, this particular medical trial is no longer recruiting patients; the listing was last updated on July 4th 2022 and first posted on October 25th 2019. Fortunately, there are 2,496 other studies presently seeking participants."

Answered by AI
~18 spots leftby Apr 2025